Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable.

Berger J, Stirnemann J, Bourgne C, Pereira B, Pigeon P, Heraoui D, Froissart R, Rapatel C, Rose C, Belmatoug N, Berger MG.

Br J Haematol. 2012 Apr;157(2):274-7. doi: 10.1111/j.1365-2141.2011.08989.x. Epub 2012 Jan 9. No abstract available.

PMID:
22224474
2.

Early access experience with VPRIV(®): recommendations for 'core data' collection.

Hughes DA, Al-Sayed M, Belmatoug N, Bodamer O, Böttcher T, Cappellini M, Cohen IJ, Eagleton T, Elstein D, Giraldo P, Jones S, Kaplinsky C, Lund A, Machaczka M, Mengel E, Pastores GM, Rosenbaum H, Sjo M, Tiling N, Tsaftaridis P, Zimran A, Weinreb N.

Blood Cells Mol Dis. 2011 Aug 15;47(2):140-2. doi: 10.1016/j.bcmd.2010.10.015. Epub 2010 Dec 13. No abstract available.

PMID:
21146428
3.

Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.

Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A.

Blood Cells Mol Dis. 2011 Jan 15;46(1):119-23. doi: 10.1016/j.bcmd.2010.07.008. Epub 2010 Aug 19.

PMID:
20727796
5.
6.

Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction.

Elstein D, Foldes AJ, Zahrieh D, Cohn GM, Djordjevic M, Brutaru C, Zimran A.

Blood Cells Mol Dis. 2011 Jun 15;47(1):56-61. doi: 10.1016/j.bcmd.2011.04.005. Epub 2011 May 4.

PMID:
21536468
7.

Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.

Elstein D, Abrahamov A, Altarescu G, Zimran A.

Blood Cells Mol Dis. 2013 Feb;50(2):140. doi: 10.1016/j.bcmd.2012.09.008. Epub 2012 Oct 22. No abstract available.

PMID:
23085428
8.

Glucocerebroside storage in normal monocyte cultures.

Hardy B, Teitelman-Weissman B, Chazan S, Neri A.

Biomed Pharmacother. 1987;41(1):40-4.

PMID:
3607254
9.

[Molecular basis of treatment in Gaucher's disease].

Pocoví M.

Med Clin (Barc). 2011 Sep;137 Suppl 1:32-8. doi: 10.1016/S0025-7753(11)70014-8. Spanish.

PMID:
22230123
10.

Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy.

Mitrovic M, Sumarac Z, Antic D, Bogdanovic A, Elezovic I, Vukosavljevic D, Ignjatovic S, Majkic-Singh N, Suvajdzic N.

Blood Cells Mol Dis. 2012 Jun 15;49(1):58-9. doi: 10.1016/j.bcmd.2012.03.003. Epub 2012 Mar 27. No abstract available.

PMID:
22459893
11.

Enzyme replacement therapy in type I Gaucher disease.

Kay AC, Saven A, Garver P, Thurston DW, Rosenbloom BF, Beutler E.

Trans Assoc Am Physicians. 1991;104:258-64. No abstract available.

PMID:
1845151
12.

Large soft-tissue masses in an adult patient with Gaucher disease.

Mahajan N, Brynes R, Yano S.

J Inherit Metab Dis. 2016 Nov;39(6):887-888. Epub 2016 Aug 9.

PMID:
27503099
13.

Does enzyme replacement therapy enhance brain-derived neurotrophic factor expression in Gaucher disease?

Agilli M, Ekinci S, Fidan G.

J Neuroimmunol. 2015 Feb 15;279:39. doi: 10.1016/j.jneuroim.2015.01.003. Epub 2015 Jan 20. No abstract available.

PMID:
25669998
14.

Enzyme replacement therapy in a child with Gaucher disease.

Masood Y, Ali AS.

J Coll Physicians Surg Pak. 2006 Dec;16(12):786-8.

PMID:
17125641
15.

Enzyme replacement therapy for Gaucher disease.

Charrow J.

Expert Opin Biol Ther. 2009 Jan;9(1):121-31. doi: 10.1517/14712590802573395 . Review.

PMID:
19063698
16.

Does enzyme replacement therapy enhance brain-derived neurotrophic factor expression in Gaucher disease?

Vairo F, Sperb-Ludwig F, Wilke M, Michellin-Tirelli K, Netto C, Camargo Neto E, Schwartz IV.

J Neuroimmunol. 2015 Jun 15;283:63. doi: 10.1016/j.jneuroim.2015.05.004. Epub 2015 May 5. No abstract available.

PMID:
26004158
17.

Gaucher disease.

Mignot C, Gelot A, De Villemeur TB.

Handb Clin Neurol. 2013;113:1709-15. doi: 10.1016/B978-0-444-59565-2.00040-X. Review.

PMID:
23622393
18.

Improvement of neurological symptoms by enzyme replacement therapy for Gaucher disease type IIIb.

Aoki M, Takahashi Y, Miwa Y, Iida S, Sukegawa K, Horai T, Orii T, Kondo N.

Eur J Pediatr. 2001 Jan;160(1):63-4.

PMID:
11195024
19.

Competing for the treasure in exceptions.

Cox TM.

Am J Hematol. 2013 Mar;88(3):163-5. doi: 10.1002/ajh.23399. Epub 2013 Feb 9. No abstract available.

20.

Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.

Camou F, Viallard JF.

Blood Cells Mol Dis. 2012 Jan 15;48(1):51-2. doi: 10.1016/j.bcmd.2011.09.005. Epub 2011 Oct 7. No abstract available.

PMID:
21983348

Supplemental Content

Support Center